Document:

Employment Agreement

 Exhibit 10.1 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into
by and between Basin Water, Inc., a Delaware corporation (the “Company”), and Michael Stark (“Executive”) on October 27, 2006, and is effective as of the 22nd day of October, 2006 (the “Effective Date”). 
 WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and subject to the conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows: 
 1. Definitions. As used in this Agreement, the following terms shall have the following meanings: 
 (a) Board. “Board” means the Board of Directors of the Company. 
 (b) Bonus. “Bonus” means an amount equal to the greater of (i) Executive’s target annual bonus for the
fiscal year in which the date of termination occurs, or (ii) the bonus awarded to Executive for the fiscal year prior to the date of termination. If any portion of the bonuses awarded to Executive consisted of securities or other property, the
fair market value thereof shall be determined in good faith by the Board. 
 (c) Cause. “Cause” means
any of the following: 
 (i) the commission of an act of fraud or embezzlement by Executive involving the Company or any
successor or affiliate thereof or Executive’s commission of any other act of dishonesty that has a material adverse impact on the Company or any successor or affiliate thereof; 
 (ii) a conviction of, or plea of “guilty” or “no contest” to, a felony by Executive or any other crime involving moral
turpitude (it being understood that violation of the motor vehicle code does not constitute such a crime); 
 (iii) any
unauthorized use or disclosure by Executive of confidential information or trade secrets of the Company or any successor or affiliate thereof; 
 (iv) Executive’s gross negligence, insubordination or material violation of any duty of loyalty to the Company or any successor or affiliate thereof or any other material misconduct on the part of Executive;

 (v) Executive’s ongoing and repeated failure or refusal to perform or neglect of Executive’s duties as required
by this Agreement, which failure, refusal or neglect continues for fifteen (15) days following Executive’s receipt of written notice from the CEO or the Board stating with specificity the nature of such failure, refusal or neglect; or

 (vi) Executive’s breach of any material provision of this Agreement; 

 provided, however, that prior to the determination that “Cause” under clause (i),
(iv), (v) or (vi) of this Section 1(c) has occurred, the Company shall (w) provide to Executive in writing, in reasonable detail, the reasons for the determination that such “Cause” exists, (x) other than with
respect to clause (v) above which specifies the applicable period of time for Executive to remedy his breach, afford Executive a reasonable opportunity to remedy any such breach, if such breach is capable of being remedied, and (y) provide
Executive an opportunity to be heard prior to the final decision to terminate the Executive’s employment hereunder for such “Cause.” The Company shall make any decision that “Cause” exists in good faith. 
 The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to
discharge or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause. 
 (d) Change in Control. “Change in Control” means and includes each of the following: 
 (i) the acquisition, directly or indirectly, by any “person” or “group” (as those terms are defined in Sections
3(a)(9), 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder) of “beneficial ownership” (as determined pursuant to Rule 13d-3 under the Exchange Act) of
securities entitled to vote generally in the election of directors (“voting securities”) of the Company that represent fifty percent (50%) or more of the combined voting power of the Company’s then outstanding voting
securities, other than: 
 (A) an acquisition by a trustee or other fiduciary holding securities under any employee benefit
plan (or related trust) sponsored or maintained by the Company or any person controlled by the Company or by any employee benefit plan (or related trust) sponsored or maintained by the Company or any person controlled by the Company; 
 (B) an acquisition of voting securities by the Company or a corporation owned, directly or indirectly by the stockholders of the Company
in substantially the same proportions as their ownership of the stock of the Company; or 
 (C) an acquisition of voting
securities pursuant to a transaction described in subsection (iii) below that would not be a Change in Control under subsection (iii); 
 Notwithstanding the foregoing, the following event shall not constitute an “acquisition” by any person or group for purposes of this Section 1(d): an acquisition of the Company’s securities by the
Company which causes the Company’s voting securities beneficially owned by a person or group to represent fifty percent (50%) or more of the combined voting power of the Company’s then outstanding voting securities; or 
 (ii) during any period of two (2) consecutive years, individuals who, at the beginning of such period, constitute the Board together
with any new director(s) (other than a director designated by a person who shall have entered into an agreement with the Company to 

  

 2 

 
effect a transaction described in clauses (i) or (iii) of this Section 1(d)) whose election by the Board or nomination for election by the
Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the two (2) year period or whose election or nomination for election was
previously so approved, cease for any reason to constitute a majority thereof; or 
 (iii) the consummation by the Company
(whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or
substantially all of the Company’s assets or (z) the acquisition of assets or stock of another entity, in each case other than a transaction: 
 (A) which results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the
Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or otherwise succeeds to the business of the Company
(the Company or such person, the “Successor Entity”)), directly or indirectly, at least a majority of the combined voting power of the Successor Entity’s outstanding voting securities immediately after the transaction; and

 (B) after which no person or group beneficially owns voting securities representing fifty percent (50%) or more of
the combined voting power of the Successor Entity; provided, however, that no person or group shall be treated for purposes of this clause (B) as beneficially owning fifty percent (50%) or more of combined voting power of the
Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction; or 
 (iv) the Company’s stockholders approve a liquidation or dissolution of the Company. 
 (e) Code.
“Code” means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations and other interpretive guidance issued thereunder. 
 (f) Excise Tax. “Excise Tax” means the excise tax imposed by Section 4999 of the Code, together with any
interest or penalties imposed with respect to such excise tax. 
 (g) Good Reason. “Good Reason” means
Executive’s voluntary resignation following any one or more of the following that is effected without Executive’s written consent: 
 (i) the relocation of the office of Executive more than fifty (50) miles from the Primary Work Locations; 
 (ii) a material reduction in the nature or scope of Executive’s responsibilities, or the assignment to Executive of duties that are materially inconsistent with Executive’s position (in each case as compared
to Executive’s responsibilities, duties or position on the Effective Date) (provided that the fact that the Company becomes a subsidiary of an 

  

 3 

 
acquirer or a division of an acquirer shall not in and of itself by considered a material reduction or change to Executive’s responsibilities, duties or
position); 
 (iii) a reduction in Executive’s base salary or target bonus as an employee of the Company, other than
pursuant to a Company-wide reduction of base salaries and target bonuses for employees of the Company generally; 
 (iv) the
Company’s failure to continue in effect compensation and benefit plans which provide Executive with benefits which are no less favorable on an aggregate basis, both in terms of the amount of benefits provided and the level of Executive’s
participation relative to other participants, to the benefits provided to Executive under the Company’s compensation and benefit plans and practices on the Effective Date; 
 (v) any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company as contemplated by
Section 9(b); 
 (vi) any change in Executive’s reporting relationship such that Executive no longer reports
directly to the CEO; or 
 (vii) the Company’s breach of any material provision of this Agreement; provided, that
Executive shall (w) provide to the Company in writing, in reasonable detail, notice of such breach and (x) afford the Company a reasonable opportunity to remedy any such breach, if such breach is capable of being remedied. 
 (h) Payment. “Payment” means any payment or distribution in the nature of compensation (within the meaning of
Section 280G(b)(2) of the Code) to or for the benefit of the Executive, whether paid or payable pursuant to this Agreement or otherwise. 
 (i) Permanent Disability. Executive’s “Permanent Disability” shall be deemed to have occurred if Executive shall become physically or mentally incapacitated or disabled or otherwise unable
fully to discharge his duties hereunder for a period of ninety (90) consecutive calendar days or for one hundred twenty (120) calendar days in any one hundred eighty (180) calendar-day period. The existence of Executive’s
Permanent Disability shall be determined by the Company on the advice of a physician chosen by the Company and the Company reserves the right to have the Executive examined by a physician chosen by the Company at the Company’s expense.

 (j) Stock Awards. “Stock Awards” means all stock options, restricted stock and such other awards
granted pursuant to the Company’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof. 
 2. Term of Agreement. Executive’s employment under this Agreement shall be for a term of three (3) years from the Effective Date (the “Employment Term”). 
 3. Services to Be Rendered. 
 (a) Duties and Responsibilities. Executive shall serve as President and Chief Operating Officer of the Company and in such capacity shall have such duties as are normally 

  

 4 

 
associated with such position, including but not limited to responsibility for the overall operation of the Company including marketing, sales, and profit
and loss responsibilities. In the performance of such duties, Executive shall report to the Chief Executive Officer (“CEO”) and shall be subject to the direction of the CEO and to such limits upon Executive’s authority as the
CEO may from time to time impose. Executive hereby consents to serve as an officer and/or director of the Company or any subsidiary or affiliate thereof without any additional salary or compensation, if so requested by the CEO or the Board.
Executive shall be employed by the Company on a full time basis. Executive’s primary place of work shall be the Company’s facility in Rancho Cucamonga, California, or such other location as may be designated by the CEO and the Board from
time to time (Rancho Cucamonga, California or such other location as designated by the CEO and the Board are referred to herein as the “Primary Work Locations”). The Company acknowledges that the Executive will not be expected to
relocate his residence to California as part of his job responsibilities. Executive understands and agrees that he may be required to travel and perform services for the Company at such other places within or outside the United States as the CEO may
direct from time to time, however, Executive’s primary place of work shall remain the Primary Work Locations. Executive shall be subject to and comply with the policies and procedures generally applicable to senior executives of the Company to
the extent the same are not inconsistent with any term of this Agreement. 
 (b) Exclusive Services. Executive shall at
all times faithfully, industriously and to the best of his ability, experience and talent perform to the satisfaction of the CEO and the Board all of the duties that may be assigned to Executive hereunder and shall devote substantially all of his
productive time and efforts to the performance of such duties. Subject to the terms of Section 6, this shall not preclude Executive from devoting time to personal and family investments or serving on community and civic boards, or participating
in industry associations, provided such activities do not interfere with his duties to the Company, as determined in good faith by the CEO and the Board. Executive agrees that he will not join any boards, other than community and civic boards (which
do not interfere with his duties to the Company), without the prior approval of the CEO and the Board. 
 4. Compensation and
Benefits. The Company shall pay or provide, as the case may be, to the Executive the compensation and other benefits and rights set forth in this Section 4, commencing as of the Effective Date unless otherwise indicated. 
 (a) Base Salary. The Company shall pay to Executive a base salary of $325,000 per year, payable in accordance with the
Company’s usual pay practices (and in any event no less frequently than monthly). Executive’s base salary shall be subject to review annually by and at the sole discretion of the Compensation Committee of the Board based on the
Company’s performance (such as profitability of the Company and growth in the Company’s market capitalization). 
  

 5 

 (b) Bonus. Executive shall be eligible to receive a bonus based on achievement of
annual targeted revenue and net income, as established by the Compensation Committee of the Board each fiscal year. If actual performance is less than 80% of target no bonus will be earned or paid. If actual performance is 80% or more of target,
then Executive shall earn and be paid a bonus as a percentage of base salary as follows: 
  

																
	 % of target achieved
	  	80	%	 	90	%	 	100	%	 	110	%	 	120	%+
	 % of salary as bonus
	  	15	%	 	30	%	 	50	%	 	60	%	 	75	%

 All interim percentages will be calculated on straight-line, pro rata basis. For this purpose, revenue and net
income shall be defined to exclude contribution from any future acquisitions, initiatives or other joint ventures of the Company, unless specifically included by the Compensation Committee of the Board, in advance and in writing. 
 In the event that the performance targets are not achieved, the Compensation Committee of the Board in its sole discretion may elect to pay a discretionary bonus of up
to 25% of base salary based on other factors not related to achievement of the performance targets. 
 (c) Benefits.
Executive shall be entitled to participate in benefits under the Company’s benefit plans and arrangements, including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior
executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the
Company to its senior executives and not otherwise specifically provided for herein. The Company shall provide executive with the following employee benefits: 
 (i) The Company shall provide Executive long-term disability insurance at its cost to the Executive in an amount equal to 75% of base
annual salary up to a maximum benefit of $30,000 per month (total benefit to be provided through a combination of “group” program offered to all employees and supplemental individual disability policy for the Executive); 
 (ii) The Company shall provide Executive life insurance at its cost in an amount equal to 3 times Executive’s annual base salary
(total benefit to be provided through Company’s basic group term life insurance plan, should one be established, and an individual term life insurance policy for the Executive); 
 (iii) The Company agrees to reimburse the Executive for out-of-pocket expenses relating to a biennial physical examination up to a maximum
of $3,000. 
 (d) Expenses. The Company shall reimburse Executive for reasonable out-of-pocket expenses incurred in
connection with the performance of his duties hereunder, subject to (i) such policies as the Company may from time to time establish, and (ii) Executive furnishing the Company with evidence in the form of receipts satisfactory to the
Company substantiating the claimed expenditures. 
 (e) Paid Time Off. Executive shall be entitled to such periods of
paid time off (“PTO”) each year as provided under the Company’s PTO policy and as otherwise provided for 

  

 6 

 
senior executive officers. Under such policy, Executive shall accrue 20 days in the first two years of employment, 25 days after two years. 
 (f) Equity Plans. 
 (i) Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to senior executive officers, as distinguished from general management, of the Company. Except as
otherwise provided in this Agreement, Executive’s participation in and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan. 
 (ii) On the date of this Agreement, Executive shall be granted a restricted stock award of 200,000 shares of the Company’s common
stock (the “Restricted Stock”) under the Company’s 2006 Equity Incentive Award Plan (the “2006 Plan”). The shares of Restricted Stock will be subject to forfeiture in the event Executive’s employment with
or service to the Company terminates prior to the vesting of the shares in accordance with the terms of this Agreement. The restrictions on such Restricted Stock shall lapse in three (3) equal annual installments commencing on the first
anniversary of the Effective Date, subject to Executive’s continued employment or service with the Company on each such date. Subject to Sections 4(g) and 5, such Restricted Stock shall be subject to the terms and conditions of the 2006 Plan
and the restricted stock award agreement pursuant to which such Restricted Stock is granted to the extent such provisions are not less favorable to Executive than the applicable provisions of this Agreement. 
 (iii) On the date of this Agreement, Executive shall be granted options to purchase 300,000 shares of the Company’s common stock at
an exercise price equal to the fair market value of the Company’s common stock on such date, as determined under the 2006 Plan. Such options shall vest and become exercisable as follows: (A) 100,000 shares subject to such option shall be
vested and exercisable on the date that the closing price of the Company’s common stock on Nasdaq (or such other stock exchange or national market system on which the Company’s common stock is then traded) equals or exceeds $15.25 per
share for a period of at least 45 continuous days within the three year period from the date of grant; (B) 100,000 shares subject to such option shall be vested and exercisable on the date that the closing price of the Company’s common
stock on Nasdaq (or such other stock exchange or national market system on which the Company’s common stock is then traded) equals or exceeds $19 per share for a period of at least 45 continuous days within the three year period from the date
of grant; and (C) 100,000 shares subject to such option shall be vested and exercisable on the date that the closing price of the Company’s common stock on Nasdaq (or such other stock exchange or national market system on which the
Company’s common stock is then traded) equals or exceeds $23.50 per share for a period of at least 45 continuous days within the four year period from the date of grant. 
 (g) Accelerated Vesting of Stock Awards. 
 (i) In the event of a Change in Control, the vesting and/or exercisability of one hundred percent (100%) of Executive’s
outstanding Stock Awards shall be automatically accelerated immediately prior to the Change in Control. 
  

 7 

 (ii) If Executive’s employment is terminated by the Company without Cause or by
Executive for Good Reason, in each case within twenty-four (24) months following a Change in Control, the vesting and/or exercisability of one hundred percent (100%) of Executive’s outstanding Stock Awards shall be automatically
accelerated as of the date of termination. 
 (iii) The vesting pursuant to clauses (i) and (ii) of this
Section 4(g) shall be cumulative. The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award. 
 5. Termination and Severance. Executive shall be entitled to receive benefits upon termination of employment only as set forth in this
Section 5: 
 (a) At-Will Employment; Termination. The Company and Executive acknowledge that Executive’s
employment is and shall continue to be at-will, as defined under applicable law, and that Executive’s employment with the Company may be terminated by either party at any time for any or no reason, with or without notice. If Executive’s
employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award or compensation other than as provided in this Agreement. Executive’s employment under this Agreement shall be terminated
immediately on the death of Executive. 
 (b) Termination without Cause or for Good Reason. 
 (i) Termination Apart From Change in Control. If Executive’s employment is terminated by the Company without Cause or by
Executive for Good Reason prior to a Change in Control or more than twenty-four (24) months following a Change in Control, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled
under any severance plan or program of the Company, the benefits provided below: 
 (A) the Company shall pay to Executive
his fully earned but unpaid base salary, when due, through the date of termination at the rate then in effect, plus all other amounts to which Executive is entitled under any compensation plan or practice of the Company at the time of termination;

 (B) subject to Executive’s continued compliance with the provisions of Section 6, Executive shall be entitled to
receive severance pay in an amount equal to Executive’s base salary as in effect immediately prior to the date of termination for the six (6) month period following the date of termination, payable in a lump sum as soon as administratively
practicable but in any event no later than two and one-half (2 1/2) months following the date of
termination; plus 
 (C) subject to Executive’s continued compliance with the provisions of Section 6, for
the period beginning on the date of termination and ending on the date which is six (6) full months following the date of termination (or, if earlier, the date on which Executive accepts employment with another employer that provides comparable
benefits in terms of cost and scope of coverage), the Company shall pay for 

  

 8 

 
and provide Executive and his dependents with healthcare benefits which are substantially the same as the benefits provided to Executive immediately prior to
the date of termination, including, if necessary, paying the costs associated with continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”); and 
 (D) subject to Executive’s continued compliance with the provisions of Section 6, Executive shall be entitled to
executive-level outplacement services at the Company’s expense, not to exceed $15,000. Such services shall be provided by a firm selected by Executive from a list compiled by the Company. 
 (ii) Termination In Connection With Change in Control. If Executive’s employment is terminated by the Company without Cause or
by Executive for Good Reason within twenty-four (24) months following a Change in Control, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any severance plan or
program of the Company, the benefits provided below: 
 (A) the Company shall pay to Executive his fully earned but unpaid
base salary, when due, through the date of termination at the rate then in effect, plus all other amounts to which Executive is entitled under any compensation plan or practice of the Company at the time of termination; 
 (B) subject to Executive’s continued compliance with the provisions of Section 6, Executive shall be entitled to receive
severance pay in an amount equal to the sum of: 
 (1) Executive’s base salary as in effect immediately prior to date of
termination for a period equal to six (6) months, payable in a lump sum as soon as administratively practicable but in any event no later than two and one-half (2  1/2) months following the date of termination; plus 
 (2) an amount equal to Executive’s Bonus for the year in which the date of termination occurs, payable in a lump sum as soon as administratively practicable but in any event no later than two and one-half (2  1/2) months following the date of termination; 
 (C) subject to Executive’s continued compliance with the provisions of Section 6, for the period beginning on the date of
termination and ending on the date which is six (6) full months following the date of termination (or, if earlier, the date on which Executive accepts employment with another employer that provides comparable benefits in terms of cost and scope
of coverage), the Company shall pay for and provide Executive and his dependents with healthcare benefits which are substantially the same as the benefits provided to Executive immediately prior to the date of termination, including, if necessary,
paying the costs associated with continuation coverage pursuant to COBRA; 
 (D) subject to Executive’s continued
compliance with the provisions of Section 6, Executive shall be entitled to executive-level outplacement 

  

 9 

 
services at the Company’s expense, not to exceed $15,000. Such services shall be provided by a firm selected by Executive from a list compiled by the
Company. 
 The payments and benefits provided for in this Section 5(b)(ii) shall only be payable in the event
Executive’s employment is terminated by the Company without Cause or by Executive for Good Reason within twenty-four (24) months following a Change in Control. If Executive’s employment is terminated by the Company without Cause or by
Executive for Good Reason prior to a Change in Control or more than twenty-four (24) months following a Change in Control, then Executive shall receive the payments and benefits described in Section 5(b)(i) and shall not be eligible to
receive any of the payments and benefits described in this Section 5(b)(ii). 
 (c) Other Termination. If
Executive’s employment is terminated by the Company for Cause or as a result of Executive’s Permanent Disability, by Executive without Good Reason or as a result of Executive’s death, or if the Employment Term expires and is not
renewed by the Company, the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall be entitled to receive (i) Executive’s fully earned but
unpaid base salary, through the date of termination at the rate then in effect, and (ii) all other amounts or benefits to which Executive is entitled under any compensation, retirement or benefit plan or practice of the Company at the time of
termination in accordance with the terms of such plans or practices, including, without limitation, any continuation of benefits required by COBRA or applicable law. In addition, if Executive’s employment is terminated by the Company for Cause
or as a result of Executive’s Permanent Disability, by Executive without Good Reason or as a result of Executive’s death, or if the Employment Term expires and is not renewed by the Company, all vesting of Executive’s unvested Stock
Awards previously granted to him by the Company shall cease and none of such unvested Stock Awards shall be exercisable following the date of such termination. The foregoing shall be in addition to, and not in lieu of, any and all other rights and
remedies which may be available to the Company under the circumstances, whether at law or in equity. 
 (d) Release. As
a condition to the Executive’s receipt of any post-termination benefits described in this Agreement, Executive shall execute a Release (the “Release”) in the form attached hereto and incorporated herein as Exhibit A or
Exhibit B, as applicable. Such Release shall specifically relate to all of Executive’s rights and claims in existence at the time of such execution, including any claims related to Executive’s employment by the Company and his
termination of employment, and shall exclude any continuing obligations the Company may have to Executive following the date of termination under this Agreement or any other agreement providing for obligations to survive Executive’s termination
of employment. It is understood that, as specified in the applicable Release, Executive has a certain number of calendar days to consider whether to execute such Release, and Executive may revoke such Release within seven (7) calendar days
after execution. In the event Executive does not execute such Release within the applicable period, or if Executive revokes such Release within the subsequent seven (7) day period, no benefits shall be payable under this Agreement. 

(e) Delay of Payments. Notwithstanding anything to the contrary in this Section 5, the parties acknowledge and agree that
any payment to be made, or benefit provided, 

  

 10 

 
to the Executive pursuant to this Section 5 shall be delayed to the extent necessary for this Agreement and such payment or benefit to comply with
Section 409A of the Code. 
 (f) Exclusive Remedy. Except as otherwise expressly required by law (e.g., COBRA) or
as specifically provided herein, all of the Executive’s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive’s employment shall cease upon such termination. In the
event of a termination of Executive’s employment with the Company, the Executive’s sole remedy shall be to receive the payments and benefits described in this Section 5. In addition, Executive acknowledges and agrees that he is not
entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section 4, including, without limitation, any excise tax imposed by
Section 4999 of the Code. 
 (g) No Mitigation. Executive shall not be required to mitigate the amount of any
payment provided for in this Section 5 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section 5 be reduced by any compensation earned by Executive as the result of employment
by another employer or self-employment or by retirement benefits; provided, however, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive under this
Section 5; provided, further, that, as provided in Section 5(b), Executive’s right to continued healthcare benefits following his termination of employment will terminate on the date on which he accepts employment with
another employer that provides comparable benefits in terms of cost and scope of coverage. 
 (h) Return of the
Company’s Property. If Executive’s employment is terminated for any reason, the Company shall have the right, at its option, to require Executive to vacate his offices prior to or on the effective date of termination and to cease all
activities on the Company’s behalf. Upon the termination of his employment in any manner, as a condition to the Executive’s receipt of any post-termination benefits described in this Agreement, Executive shall immediately surrender to the
Company all lists, books and records of, or in connection with, the Company’s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the
property of the Company. Executive shall deliver to the Company a signed statement certifying compliance with this Section 5(h) prior to the receipt of any post-termination benefits described in this Agreement. 
 (i) Waiver of the Company’s Liability. Executive recognizes that his employment is subject to termination with or without
Cause for any reason and therefore Executive agrees that Executive shall hold the Company harmless from and against any and all liabilities, losses, damages, costs and expenses, including but not limited to, court costs and reasonable
attorneys’ fees, which Executive may incur as a result of the termination of Executive’s employment. Executive further agrees that Executive shall bring no claim or cause of action against the Company for damages or injunctive relieve
based on a wrongful termination of employment. Executive agrees that the sole liability of the Company to Executive upon termination of this Agreement shall be that determined by this Section 5. In the event this covenant is more restrictive
than permitted by laws of the jurisdiction in which the Company seeks enforcement thereof, this covenant shall be limited to the extent permitted by law. 
  

 11 

 6. Certain Covenants. 
 (b) Noncompetition. Except as may otherwise be approved by the CEO and the Board, during the term of Executive’s employment,
Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or otherwise aid or assist in any manner, any firm, corporation, partnership,
proprietorship or other business that engages in any county, city or part thereof in the United States and/or any foreign country in a business which competes directly or indirectly (as determined by the CEO and the Board) with the Company’s
business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such business in such county, city or part thereof or continues to
solicit customers or potential customers therein; provided, however, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are traded on any national securities exchange if Executive
(x) is not a controlling person of, or a member of a group which controls, such entity; or (y) does not, directly or indirectly, own one percent (1%) or more of any class of securities of any such entity. 
 (c) Confidentiality. Executive hereby agrees that, other than as Executive determines in good faith is necessary or appropriate in
the discharge of his duties hereunder, during the term of this Agreement and thereafter, he shall not, directly or indirectly, disclose or make available to any person, firm, corporation, association or other entity for any reason or purpose
whatsoever, any Confidential Information (as defined below). Executive further agrees that, upon termination of his employment with the Company, all Confidential Information in his possession that is in written or other tangible form (together with
all copies or duplicates thereof, including computer files) shall be returned to the Company and shall not be retained by Executive or furnished to any third party, in any form except as provided herein; provided, however, that, this
Section 6(b) shall not apply to Confidential Information that (i) was publicly known at the time of disclosure to Executive, (ii) becomes publicly known or available thereafter other than by any means in violation of this Agreement or
any other duty owed to the Company by Executive, (iii) is lawfully disclosed to Executive by a third party, (iv) is required to be disclosed by law or by any court, arbitrator, mediator or administrative or legislative body (including any
committee thereof) with actual or apparent jurisdiction to order Executive to disclose or make accessible any information, or (v) is related to any litigation, arbitration or mediation between the parties, including, but not limited to, the
enforcement of this Agreement. As used in this Agreement, the term “Confidential Information” means: confidential information disclosed to Executive or known by Executive as a consequence of or through Executive’s relationship
with the Company about the customers, employees, business methods, public relations methods, organization, procedures or finances, including, without limitation, information of or relating to customer lists, product lists, product road maps,
technology specifications or other information related to the products and services of the Company and its affiliates. Nothing herein shall limit in any way any obligation Executive may have relating to Confidential Information under any other
agreement with or promise to the Company. 
 (d) Solicitation of Employees. Executive shall not during the term of
Executive’s employment and for the applicable severance period for which Executive receives severance benefits following any termination hereof pursuant to Section 5(b) above ((regardless of whether Executive receives such severance
benefits in a lump sum payment) (the “Restricted 

  

 12 

 
Period”), directly or indirectly, solicit or encourage to leave the employment of the Company or any of its affiliates, any employee of the
Company or any of its affiliates. 
 (e) Solicitation of Prospective Customers. Executive shall not during the
Restricted Period, directly or indirectly, solicit the business of any person or entity that is a Prospective Customer (as defined below) or a customer or client of the Company. As used herein, “Prospective Customer” shall mean any
person or entity whose business is being actively sought or in any way solicited, or known by Executive to be a person or entity whose business is the subject of possible solicitation by the Company. Executive expressly acknowledges that the length
of time involved in soliciting and obtaining the business of new customers can be as long as two (2) years. 
 (f)
Assignment of Inventions. 
 (i) Inventions. Executive will promptly disclose in writing to the Company complete
information concerning each and every invention, discovery, improvement, device, design, apparatus, practice, process, software or computer program, method or product, whether or not patentable or copyrightable, made, developed, perfected, devised,
conceived or first reduced to practice by Executive, either solely or in collaboration with others, during Executive’s employment under this Agreement, whether or not during regular working hours, relating either directly or indirectly to the
business, products or practices of the Company (hereinafter referred to as the “Inventions”). Executive, to the extent that he has the legal right to do so, hereby acknowledges that any and all of the Inventions are the property of
the Company and hereby assigns and agrees to assign to the property of the Company any and all of Executive’s right, title and interest in and to any and all of the Inventions without further payment (it being agreed that any costs of
effectuating such assignment shall be paid by the Company). 
 (ii) Future Inventions. As to any future Inventions made
by the Executive which relate solely to the business, products or practices of the Company and which are first conceived or reduced to practice during the term of Executive’s employment with the Company, but which are claimed for any reason to
belong to an entity or person other than the Company, the Executive will promptly disclose the same in writing to the Company and shall not disclose the same to others if the Company, within twenty (20) days thereafter, shall claim ownership of
such Inventions under the terms of this Agreement. 
 (iii) Limitations. Pursuant to Section 2870 of the
California Labor Code, the provisions of this Section 6(e) shall not apply to any Invention meeting the following conditions (an “Excluded Invention”): 
 (A) such Invention was developed entirely on the Executive’s own time; and 
 (B) such Invention was made without the use of any Company equipment, supplies, facilities or trade secret information; and 

 

 13 

 (C) such Invention does not relate (x) directly to the business of the Company, or
(y) to the Company’s actual or demonstrably anticipated research or development; and 
 (D) such Invention does not
result from any work performed by Executive for the Company. 
 (g) Rights and Remedies Upon Breach. If Executive
breaches or threatens to commit a breach of any of the provisions of this Section 6 (the “Restrictive Covenants”), the Company shall have the following rights and remedies, each of which rights and remedies shall be independent
of the other and severally enforceable, and all of which rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity: 
 (i) Specific Performance. The right and remedy to have the Restrictive Covenants specifically enforced by any court having equity
jurisdiction, all without the need to post a bond or any other security or to prove any amount of actual damage or that money damages would not provide an adequate remedy, it being acknowledged and agreed that any such breach or threatened breach
will cause irreparable injury to the Company and that money damages will not provide adequate remedy to the Company; and 
 (ii) Cessation of Payments, Accounting and Indemnification. The right and remedy to cease all payments to Executive under Section 5(b) and to require Executive (i) to account for and pay over to the Company all
compensation, profits, monies, accruals, increments or other benefits derived or received by Executive or any associated party deriving such benefits as a result of any such breach of the Restrictive Covenants; and (ii) to indemnify the Company
against any other losses, damages (including special and consequential damages), costs and expenses, including actual attorneys’ fees and court costs, which may be incurred by them and which result from or arise out of any such breach or
threatened breach of the Restrictive Covenants. 
 (g) Severability of Covenants/Blue Penciling. If any court
determines that any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If
any court determines that any of the Restrictive Covenants, or any part thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such
provision and, in its reduced form, such provision shall then be enforceable and shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope
or the length of their term. 
 (h) Enforceability in Jurisdictions. The Company and Executive intend to and do hereby
confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants wholly unenforceable
by reason of the breadth of such scope or otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the Company to the relief provided above 

  

 14 

 
in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective
jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants. 
 (i) Definitions. For purposes of this Section 6, the term “Company” means not only Basin Water, Inc., but also any company, partnership or entity which, directly or indirectly, controls,
is controlled by or is under common control with Basin Water, Inc. 
 7. Parachute Payments. 
 (a) Best Pay Provision. Anything in this Agreement to the contrary notwithstanding, in the event it shall be determined that any
Payment under this Agreement would, when combined with all other Payments Executive receives from the Company or any successor or parent or subsidiary thereof, but for this Section 7 be subject to the Excise Tax, then such Payments shall be
either (a) the full amount of such Payments or (b) such lesser amount (with cash payments being reduced before stock option compensation) as would result in no portion of the Payments being subject to the Excise Tax, whichever of the
foregoing amounts, taking into account the applicable federal, state and local employment taxes, income taxes and the Excise Tax, results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payments notwithstanding that
all or some portion of the Payments may be subject to the Excise Tax. 
 (b) Determinations. All determinations
required to be made under this Section 7, including whether and to what extent the Payments shall be reduced and the assumptions to be utilized in arriving at such determination, shall be made by the certified public accounting firm used by the
Company immediately prior to the Change in Control or, if such firm declines to serve, such other nationally recognized certified public accounting firm as may be designated by the Executive (the “Accounting Firm”). The Accounting
Firm shall provide detailed supporting calculations both to the Company and the Executive at such time as is requested by the Company. All fees and expenses of the Accounting Firm shall be borne solely by the Company. Any determination by the
Accounting Firm shall be binding upon the Company and the Executive. For purposes of making the calculations required by this Section 7, the Accounting Firm may make reasonable assumptions and approximations concerning applicable taxes and may
rely on reasonable, good-faith interpretations concerning the application of Sections 280G and 4999 of the Code. 
 8. Insurance. The
Company shall have the right to take out life, health, accident, “key-man” or other insurance covering Executive, in the name of the Company and at the Company’s expense in any amount deemed appropriate by the Company. Executive shall
assist the Company in obtaining such insurance, including, without limitation, submitting to any required examinations and providing information and data required by insurance companies. Executive shall have no interest in any such policies obtained
by the Company. 
 9. Arbitration. Any dispute, claim or controversy based on, arising out of or relating to Executive’s
employment or this Agreement shall be settled by final and binding arbitration in San Diego County, California, before a single neutral arbitrator in accordance with the National Rules for the Resolution of Employment Disputes (the
“Rules”) of the American Arbitration 

  

 15 

 
Association, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. Arbitration may be compelled pursuant to
the California Arbitration Act (Code of Civil Procedure §§ 1280 et seq.). If the parties are unable to agree upon an arbitrator, one shall be appointed by the AAA in accordance with its Rules. Each party shall pay the fees of
its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; however, Executive and the Company agree that, to the extent permitted by law, the arbitrator may, in his discretion, award reasonable
attorneys’ fees to the prevailing party. Other costs of the arbitration, including the cost of any record or transcripts of the arbitration, AAA’s administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne
by the Company. This Section 9 is intended to be the exclusive method for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive’s employment; provided, however,
that neither this Agreement nor the submission to arbitration shall limit the parties’ right to seek provisional relief, including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil
Procedure § 1281.8 or any similar statute of an applicable jurisdiction. Seeking any such relief shall not be deemed to be a waiver of such party’s right to compel arbitration. Both Executive and the Company expressly waive their right to
a jury trial. 
 10. General Relationship. Executive shall be considered an employee of the Company within the meaning of all federal,
state and local laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers’ compensation, industrial accident, labor and taxes. 
 11. Miscellaneous. 
 (a) Modification; Prior Claims. This Agreement sets forth the entire understanding of the parties with respect to the subject matter hereof, supersedes all existing agreements between them concerning such subject matter, including,
without limitation, that certain Employment Agreement dated as of October 1, 2005, and may be modified only by a written instrument duly executed by each party. 
 (b) Assignment; Assumption by Successor. The rights of the Company under this Agreement may, without the consent of Executive, be
assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly, acquires all or substantially all of the
assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and to agree to perform
this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; provided, however, that no such assumption shall relieve the Company of its obligations
hereunder. As used in this Agreement, the “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law
or otherwise. 
  

 16 

 (c) Survival. The covenants, agreements, representations and warranties contained
in or made in Sections 1, 5, 6, 7, 9 and 11 of this Agreement shall survive any termination of Executive’s employment. 
 (d) Third-Party Beneficiaries. This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement. 
 (e) Waiver. The failure of either party hereto at any time to enforce performance by the other party of any provision of this
Agreement shall in no way affect such party’s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of any provision hereof be deemed to be a waiver by such party of any other breach of the same or any other
provision hereof. 
 (f) Section Headings. The headings of the several sections in this Agreement are inserted solely
for the convenience of the parties and are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof. 
 (g) Notices. All notices, requests and other communications hereunder shall be in writing and shall be delivered by courier or other means of personal service (including by means of a nationally recognized
courier service or professional messenger service), or sent by telex or telecopy or mailed first class, postage prepaid, by certified mail, return receipt requested, in all cases, addressed to: 
 If to the Company or the Board: 
 Basin Water, Inc. 
 8731 Prestige Court 
 Rancho Cucamonga, CA 91730 
 Attention: Chairman of the Compensation Committee 
 If to Executive: 
 Michael Stark 
 4630 Magnolia Cove Drive, Apt. 111 
 Kingwood, TX 77345 
 All notices, requests and other communications shall be deemed given on the date of actual receipt or delivery as evidenced by written receipt, acknowledgement or other
evidence of actual receipt or delivery to the address. In case of service by telecopy, a copy of such notice shall be personally delivered or sent by registered or certified mail, in the manner set forth above, within three business days thereafter.
Any party hereto may from time to time by notice in writing served as set forth above designate a different address or a different or additional person to which all such notices or communications thereafter are to be given. 
 (h) Severability. All Sections, clauses and covenants contained in this Agreement are severable, and in the event any of them shall
be held to be invalid by any court, 

  

 17 

 
this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein. 
 (i) Governing Law and Venue. This Agreement is to be governed by and construed in accordance with the laws of the State of
California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections 6 and 9, any suit brought hereon shall be brought in the state
or federal courts sitting in San Diego, California, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and
consents to service of process in any manner authorized by California law. 
 (j) Non-transferability of Interest. None
of the rights of Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution upon the death of Executive.
Any attempted assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this Agreement shall be void.

 (k) Gender. Where the context so requires, the use of the masculine gender shall include the feminine and/or neuter
genders and the singular shall include the plural, and vice versa, and the word “person” shall include any corporation, firm, partnership or other form of association. 
 (l) Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same Agreement. 
 (m) Construction. The language in all parts of this
Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly for or against any of the parties hereto. Without limitation, there shall be no presumption against any party on the ground that such party was
responsible for drafting this Agreement or any part thereof. 
 (n) Withholding and other Deductions. All compensation
payable to Executive hereunder shall be subject to such deductions as the Company is from time to time required to make pursuant to law, governmental regulation or order. 
 (o) Section 409A of the Code. This Agreement shall be interpreted, construed and administered in a manner that satisfies the
requirements of Section 409A of the Code. Notwithstanding any provision of this Agreement to the contrary, the Company may adopt such amendments to this Agreement or adopt other policies and procedures (including amendments, policies and
procedures with retroactive effect), or take any other actions, that the Company determines are necessary to comply with the requirements of Section 409A of the Code. 
 (Signature Page Follows) 
  

 18 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.

  

			
	 BASIN WATER, INC.

		
	 By:
	 	 /s/ Peter Jensen

	 Name:
	 	 Peter Jensen

	 Title:
	 	 Chief Executive Officer

	
	 /s/ Michael Stark

	 Michael Stark

 [SIGNATURE PAGE TO EMPLOYMENT AGREEMENT] 

 EXHIBIT A 
 RELEASE 
 (INDIVIDUAL TERMINATION)

 Certain capitalized terms used in this Release are defined in the Employment Agreement (the “Agreement”) which I have
executed and of which this Release is a part. 
 I hereby confirm my obligations under Section 6 of the Agreement. 
 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not
extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby
expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company. 
 Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their
officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and obligations of
every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment
with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or
in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims
or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of disputed compensation; claims
pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”); the
federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful
discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from
its obligation to indemnify me pursuant to the Company’s indemnification obligation pursuant to agreement or applicable law. 
 I
acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition
to anything of value to which I was already entitled. I further acknowledge that I have been 

 
advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the
date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily execute this Release
earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; and (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be
the eighth day after this Release is executed by me. 
  

			
	MICHAEL STARK
	
	  
		
	Date:	 	  

  

 2 

 EXHIBIT B 
 RELEASE 
 (GROUP TERMINATION) 
 Certain capitalized terms used in this Release are defined in the Employment Agreement (the “Agreement”) which I have executed and of
which this Release is a part. 
 I hereby confirm my obligations under Section 6 of the Agreement. 
 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not
extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.” I hereby
expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company. 
 Except as otherwise set forth in this Release, I hereby release, acquit and forever discharge the Company, its parents and subsidiaries, and their
officers, directors, agents, servants, employees, shareholders, successors, assigns and affiliates, of and from any and all claims, liabilities, demands, causes of action, costs, expenses, attorneys fees, damages, indemnities and obligations of
every kind and nature, in law, equity, or otherwise, known and unknown, suspected and unsuspected, disclosed and undisclosed (other than any claim for indemnification I may have as a result of any third party action against me based on my employment
with the Company), arising out of or in any way related to agreements, events, acts or conduct at any time prior to the date I execute this Release, including, but not limited to: all such claims and demands directly or indirectly arising out of or
in any way connected with my employment with the Company or the termination of that employment, including but not limited to, claims of intentional and negligent infliction of emotional distress, any and all tort claims for personal injury, claims
or demands related to salary, bonuses, commissions, stock, stock options, or any other ownership interests in the Company, vacation pay, fringe benefits, expense reimbursements, severance pay, or any other form of disputed compensation; claims
pursuant to any federal, state or local law or cause of action including, but not limited to, the federal Civil Rights Act of 1964, as amended; the federal Age Discrimination in Employment Act of 1967, as amended (“ADEA”); the
federal Employee Retirement Income Security Act of 1974, as amended; the federal Americans with Disabilities Act of 1990; the California Fair Employment and Housing Act, as amended; tort law; contract law; statutory law; common law; wrongful
discharge; discrimination; fraud; defamation; emotional distress; and breach of the implied covenant of good faith and fair dealing; provided, however, that nothing in this paragraph shall be construed in any way to release the Company from
its obligation to indemnify me pursuant to the Company’s indemnification obligation pursuant to agreement or applicable law. 
 I
acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Agreement for the waiver and release in the preceding paragraph hereof is in addition
to anything of value to which I was already entitled. I further acknowledge that I have been 

 
advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the
date I execute this Release; (B) I have the right to consult with an attorney prior to executing this Release; (C) I have forty-five (45) days to consider this Release (although I may choose to voluntarily execute this Release
earlier); (D) I have seven (7) days following the execution of this Release by the parties to revoke the Release; (E) this Release shall not be effective until the date upon which the revocation period has expired, which shall be the
eighth day after this Release is executed by me; and (F) I have received with this Release a detailed list of the job titles and ages of all employees who were terminated in this group termination and the ages of all employees of the Company in
the same job classification or organizational unit who were not terminated. 
  

			
	MICHAEL STARK
	
	  
		
	Date:	 	  

  

 2Supply Agreement, dated July 18, 1994

 Exhibit 10.19 
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED. 
 SUPPLY AGREEMENT FOR STERITECH COMPOUND [ * ] 
 Agreement, effective as of July 18, 1994, by and between [ * ] , and STERITECH, INC., a California
corporation with offices at 2525 Stanwell Drive, Concord, California 94520 (“Steritech”). 
 WITNESSETH:

 WHEREAS, Steritech is the owner of certain intellectual property rights respecting, and engages in certain
research regarding the uses of, the compound designated [ * ] (the “Compound”); and 
 WHEREAS, [ * ] is able to synthesize and supply the Compound, manufactured in accordance with current U.S. Good Manufacturing Practices (“GMP”) standards and meeting Food and Drug Administration
(“FDA”) quality standards; 
 NOW, THEREFORE, in consideration of the mutual
covenants herein contained, the parties hereby agree as follows: 
 1. Promptly upon mutual agreement regarding amount of Compound to
be manufactured as set forth in a requisition (sample shown in Exhibit A), [ * ] shall commence, and thereafter, as expeditiously as possible, shall proceed with the synthesis of Compound and shall deliver the completed Compound, meeting the
analytical specifications defined in Exhibit B, to Steritech within a maximum time of ninety (90) days from date of requisition. [ * ] also agrees to deliver to Steritech all batch records and analytical data confirming conformance to
specifications for each raw material, isolated intermediate and final product. The first requisition shall be for a minimum of ten (10) kilograms of Compound and future requisitioned amounts shall be within the limits of [ * ] present
manufacturing capacity. 
 2. In consideration of the supply by [ * ] of the Compound as provided in this Agreement, Steritech
agrees that it shall pay to [ * ] the amount agreed upon in writing at the time of the request to manufacture. Such payment shall be made by Steritech upon final delivery by [ * ] of the Compound conforming to agreed upon
specifications and all test and batch records relating to its preparation. Steritech agrees to pay [ * ] sixty thousand dollars ($60,000) for the first requisitioned material and future costs shall be commensurate allowing for mutually agreed
upon changes in process parameters. 
 3. In connection with the performance of this Agreement, [ * ] shall: 
 a. Purchase, test and release raw materials and intermediates as defined in specifications agreed upon by both parties. Raw
materials shall conform to American Chemical Society (ACS), United States Pharmacopoeia / National Formulary (USP/NF) or European Pharmacopoeia (EP) specifications. Any exceptions to these specifications are shown in Exhibit C of this contract. All
isolated intermediates as well as the Compound shall be analyzed at each step by [ * ] to adequately identify, characterize and assess purity of materials per attributes, 

  

 1 

 
limits and test methods specified by Steritech. Such test methods may include spectral and/or chromatographic characterization and elemental analysis in
conformance with stringent elemental analyses established by the Journal of Medicinal Chemistry or equivalent when requested by Steritech. 
 b. Prepare data sheets, spectral/chromatographic sheets, and description of preparative methods for all materials. [ * ] shall utilize a data sheet format that conforms to the requirements for a Batch
Production Record as described in Part 211 of Title 21 of the Code of Federal Regulations. Further, Steritech reserves the right to review and approve all such records prior to their use in the production of intermediates or bulk drug substances.
The preparative methods shall be sufficiently detailed for filing with the FDA as bulk manufacturing processes. This includes details of sources, purities and lot numbers of all raw materials and solvents used, their quantities, and detailed
methodology of isolation and/or purification procedures. 
 c. Retain samples of Compound for one year after
manufacture. Samples of this material will be made available to Steritech upon request. 
 d. Analyze Compound by test
methods agreed upon by both parties that conform to USP or EP methods. Upon Steritech’s request and approval, samples of Compound shall be made available to a third party for analytical testing. 
 e. Provide Steritech with a copy of each data sheet or Batch Production Record and all pertinent analytical data for its review and
approval prior to delivery of each batch of Compound. 
 f. Provide evidence of the use of validated cleaning methods
for equipment as per present manufacturing standards. 
 4. [ * ] shall also provide Steritech with samples of specified
intermediates defined in the requisition (Exhibit A) for monitoring purposes only. Results obtained by such studies will have no effect on the acceptance and approval by Steritech of the final Compound. 
 5. [ * ] shall comply with all Government health and safety regulations: 
 a. FDA: [ * ] shall be registered with the FDA as a manufacturer of bulk drug substances. [ * ] shall inform
Steritech of any facilities inspection or any other FDA action relative to the continued approval of its facilities by FDA for the manufacture of bulk drug substances and shall supply a copy of any FDA Form 483 or any other regulatory compliance
letter or notice issued by the FDA to [ * ] during the term of this contract. Facilities shall meet FDA standards in accordance with the current Good Manufacturing Practices (cGMP). If during the course of the contract FDA inspections cite
deficiencies which, in the opinion of Steritech, are judged to compromise the purity and/or quality of materials to be delivered, Steritech will have the right, by written notice to [ * ] and without incurring liability, to terminate the
contract, without limitation of any other rights or remedies. An FDA facilities Drug Master File is available and on file with the FDA and is updated annually as required by FDA regulations. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
OF THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 2. 

 b. Occupational Safety and Health Administration (OSHA): [ * ] shall comply
with OSHA regulations. 
 c. Environmental Protection Agency (EPA): [ * ] shall comply with EPA regulations
regarding the discharge of water and air pollutants and for assuring that disposal of all chemicals residues meet current EPA regulations. 
 d. Good laboratory safety controls and procedures shall be followed by [ * ] in carrying out the activities for this project. 
 6. In connection with the performance of the Agreement, Steritech shall: 
 a. Furnish reference samples needed for the required analyses. 
 b. Retain samples of the Compound for internal use and to support a Compound Drug Master File and Steritech’s Investigational
New Drug (IND) application. 
 c. Approve all specifications and production records prior to manufacture of the
Compound. 
 7. Upon approval by Steritech, materials prepared shall be shipped as directed by Steritech. Containers shall be
previously approved by Steritech. Batch records and required test samples must be received and approved prior to acceptance of the bulk shipment. Compound that does not meet the agreed upon specifications shall not be accepted under this agreement.

 8. Steritech reserves the right to inspect [ * ] facilities, equipment, and controls for the manufacture of Steritech’s
compounds at dates and times that are mutually acceptable. Steritech also reserves the right to delegate such inspections to qualified third party auditors of its choosing as long as such auditors are bound by the same confidentiality agreement
currently in effect between the two parties. 
 9. [ * ] further consents to the review by Steritech of [ * ] Master
File for the Compound and the facility’s Drug Master File. If requested by Steritech, [ * ] will provide such additional form of consent or authorization as the FDA may require in connection with such review. Steritech may include this
Agreement and/or such additional form in Steritech’s IND application. 
 10. This agreement shall apply to all requisitions of
the Compound within three (3) years of the signing of this agreement unless superseded by a mutually agreed upon in subsequent agreement. This agreement does not obligate Steritech to request or pay for a specified number of batches or quantity
of the Compound. Recognizing that a timely supply of Compound is critical to the ability of Steritech to proceed in its business, [ * ] shall give ninety (90) days notice in writing if it does not intend to accept one or several future
requests for Compound under the terms of this agreement. 
 11. The Nondisclosure Agreement dated April 13, 1993 between the
parties shall be deemed incorporated herein by reference and apply to all information disclosed by Steritech to [ * ] 

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
OF THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 3. 

 
and all information generated hereunder. The chemicals prepared or handled under this contract shall be regarded as proprietary in nature. Under no
circumstances shall chemicals or any information associated with these chemicals be released or divulged without prior approval of Steritech. 
 12. [ * ] will make prompt written disclosure to Steritech, will hold in trust for the sole right and benefit of Steritech, and hereby assigns to Steritech all right, title and interest in and to any inventions, developments,
improvements or trade secrets, including without limitation optimized procedures, which [ * ] its employees or agents may solely or jointly conceive or reduce to practice, in the course of or as a result of the work hereunder concerning the
Compound (including without limitation processes associated with its manufacture). [ * ] will assist Steritech in every proper way to obtain and enforce United States and foreign proprietary rights relating to any and all inventions,
development, improvements or trade secrets of Steritech in any and all countries. To that end [ * ] will execute, verify and deliver such documents and perform such other acts (including appearing as a witness) Steritech may reasonably
request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such proprietary rights and the assignment thereof. In addition, [ * ] will execute, verify and deliver assignments of such proprietary rights to
Steritech or its designee. Steritech shall compensate [ * ] at a reasonable rate for the time actually spent by [ * ] at Steritech’s request on such assistance. In the event Steritech is unable for any reason, after reasonable
effort, to secure [ * ] signature on any document needed in connection with the actions specified in the preceding paragraph, [ * ] hereby irrevocably designates and appoints Steritech and its duly authorized officers and agents as its
agent and attorney-in-fact, to act for and in its behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if
executed by [ * ] 
 13. If any provision or clause of this Agreement, or portion thereof, shall for any reason be held to be
invalid, illegal or unenforceable, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, but this Agreement shall be construed as if such provision or clause, or portion thereof, had never been
contained in this Agreement, and there shall be deemed substituted therefor such other provision or clause, or portion thereof, as will most nearly accomplish the intent of the parties as expressed in this Agreement to the fullest extent permitted
by law. 
 14. This Agreement shall be governed by and construed and enforced under the internal laws of the State of California (and
not its principles of conflicts of law). The parties consent and submit to the jurisdiction of the courts of the State of California and of the United States for a judicial district within the territorial limits of the State of California for all
purposes with respect to any action or proceeding in connection with this Agreement. 
 IN WITNESS
WHEREOF, the parties have caused this Agreement to be duly executed and delivered by their respective authorized representatives as of the effective date first above written. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
OF THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 4. 

									
	 STERITECH, INC.
	 		 	 [ * ]

					
	 By:
	 	 /s/ Stephen Isaacs
	 		 	 By:
	 	 [ * ]

									
	 Name (Print):
	 	 Stephen Isaacs
	 		 	 Name (Print):
	 	 [ * ]

	 Title (Print):
	 	 President/CEO
	 		 	 Title (Print):
	 	 President

									
	 Date:
	 	 July 22, 1994
	 		 	 Date:
	 	 July 21, 1994

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
OF THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 5. 

 EXHIBIT A 
  

									
	 STERITECH, INC.
 2525 Stanwell Dr.,
Suite 300
 Concord, CA 94520
 510-603-9071 FAX
510-603-9099
	  	PAGE
NO.	  	P.O. No.	  	ORDER DATE	  	VEND.
	  	1	  	1695	  	7/15/94	  	
	  		  		  		  	
	  	PURCHASE ORDER

  

																											
	 V
 E
 N
 D
 O
 R
	  	[ * ]	  	S
H
I
P	  	[ * ]
	  		  		  	
	  		  	T
O	  	

															
						
	ORDER DATE	  	CANCELLATION DATE	  	SHIP VIA	  	F.O.B.	  		  	TERMS
	7/15/94	  		  	to be determined	  		  		  	Net 30 days
						
	RESALE NO.	  	RESPONSIBILITY	  		  	BRANCH	  		  	
	 ITEM NO.
 MFG. NO.
	  	DESCRIPTION	  	 REG. DATE
 LOCATION
	  	 QUANTITY
 ORDERED
	  	 QUANTITY
 BACK ORD.
	  	QTY REC.	  	UNIT PRICE	  	EXTENSION
	[ * ]	  	 [ * ] *
 [ * ]
	  		  	10 Kg	  		  		  	$60,000	  	

							
	  
 To be delivered to Steritech by Sept. 16,
1994.
  
 Shipping requirements: Send 10g to Steritech plus one gram
(1g) from each additional container. Upon approval, send rest of order to [ * ] unless specified otherwise.
  
 Intermediates requested: Send to Steritech samples 1g of [ * ] [ * ] [ * ] and [ * ] prepared and used for the
manufacture of this lot of [ * ] 
  
 * As per agreement signed
July 18, 1994. “Supply Agreement for Steritech Compound [ * ] 
  
	  	
		  	SUBTOTAL	  	$60,000	  	
				
		  	PURCHASE ORDER NO.	  	1695	  	
				
		  		  	TOTAL ORDER
VALUE	  	

  

	
	
	   
	AUTHORIZED SIGNATURE

 ORDER TERMS AND CONDITIONS 
  

	1.	INVOICES must bear exact same prices and terms or authorization for changes must be received from our company in writing prior to shipping. 

  

	2.	Goods not in accordance with specifications will be rejected and held at vendor’s risk awaiting disposal. Vendor must pay freight on all rejected material.

  

	3.	The right is reserved, to cancel all or part of this order if not delivered within the time specified. 

  

	4.	Packing slips must accompany all shipments. 

  

	5.	By acceptance of this order, vendor warrants that all merchandise shipped under this order does comply with all laws and regulations of Federal and State governments.

  

	6.	Back orders must be prepaid when less than a minimum freight shipment. 

  

	7.	In the event of interruption of our business in whole or in part by reason of fire, flood, windstorm, earthquake, war, strike, embargo, acts of God, governmental action, or any
causes beyond our control, we shall have the option of canceling undelivered orders in whole or part. 

  

	8.	Acceptance of the purchase order, or shipment of any part of it will constitute an agreement to all of its specifications as to terms, delivery and prices.

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 EXHIBIT B 
 Specifications for [ * ] 
 [ * ] [ * ] 
  

							
	I.	  	Identity	  		  	
				
		  	A.	  	IR spectrum	  	spectrum compares with reference
				
		  	B.	  	NMR	  	spectrum compares with reference
				
		  		  		  	[ * ]
				
	II.	  	Purity	  		  	
				
		  	A.	  	HPLC	  	[ * ] of reference standard by peak area
				
		  		  		  	[ * ]
				
		  	B.	  	Loss on Drying	  	[ * ] by weight

 For documentation purposes only, the following other analyses of purity shall
also be completed: 
  

			
	Elemental Analysis	  	Analysis shall be [ * ]
		
	NMR	  	Analysis shall be [ * ]
		
	HPLC	  	Analysis shall be [ * ]

  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 EXHIBIT C 
 Raw materials to be used in the manufacture of Steritech’s [ * ] [ * ] [ * ] that do not conform to ACS, USP/NF or EP specifications for these reagents, or such specifications are not available: 
  

			
	 [ * ]
 Part Number and
Effective date
	  	 Description and Vendor Information

	 [ * ]
 22 Feb 93
	  	 [ * ]
 Vendor: [ * ]

		
	 [ * ]
 28 Mar 94
	  	 [ * ] 
 Vendor: [ * ] (cat. no. [ *
] )

		
	 [ * ]
 8 Feb 94
	  	 [ * ] 
 Vendor: [ * ] (cat. no. [ *
] or equivalent)

		
	 [ * ]
 8 Feb 94
	  	 [ * ] 
 Vendor: [ * ] (cat. no. [ *
] or equivalent)

		
	 [ * ]
 18 Feb 94
	  	 [ * ] 
 Vendor: [ * ] (cat. no. [ *
] or equivalent)

		
	 [ * ]
 7 Mar 94
	  	 [ * ] 
 Vendor: [ * ] (cat. no. N/A), [
* ] (cat. no. [ * ] or equivalent)

		
	 [ * ]
 8 Feb 94
	  	 [ * ] 
 Vendor: [ * ] (cat. no.
N/A)

 All other raw materials used in this manufacturing process are of ACS, USP/NF or
EP Grade. 
  

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
OF THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]